Equities Analysts Offer Predictions for CGTX Q1 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Cognition Therapeutics in a research note issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.07) EPS.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same period in the previous year, the firm posted ($0.27) earnings per share.

CGTX has been the subject of a number of other research reports. B. Riley raised shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the company from $1.00 to $1.50 in a research report on Thursday, December 19th. Chardan Capital decreased their price objective on Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 21st. Finally, Brookline Capital Management raised Cognition Therapeutics to a “strong-buy” rating in a research report on Monday, January 27th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $7.50.

Cognition Therapeutics Stock Performance

NASDAQ:CGTX opened at $0.44 on Tuesday. The company’s 50-day simple moving average is $0.57 and its 200-day simple moving average is $0.55. Cognition Therapeutics has a fifty-two week low of $0.34 and a fifty-two week high of $2.95. The stock has a market capitalization of $18.35 million, a P/E ratio of -0.46 and a beta of 1.03.

Institutional Trading of Cognition Therapeutics

Several large investors have recently bought and sold shares of the stock. Virtu Financial LLC raised its holdings in shares of Cognition Therapeutics by 40.1% in the fourth quarter. Virtu Financial LLC now owns 80,180 shares of the company’s stock worth $56,000 after buying an additional 22,949 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Cognition Therapeutics by 8.9% in the 4th quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock valued at $247,000 after acquiring an additional 28,705 shares during the period. SG Americas Securities LLC acquired a new position in shares of Cognition Therapeutics in the 4th quarter valued at $26,000. Two Sigma Investments LP raised its stake in Cognition Therapeutics by 372.2% in the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock worth $38,000 after acquiring an additional 42,321 shares during the last quarter. Finally, Sigma Planning Corp lifted its position in Cognition Therapeutics by 211.6% during the 4th quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock worth $431,000 after acquiring an additional 417,300 shares during the period. Hedge funds and other institutional investors own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.